Author

Tatiana Omelchenko

Memorial Sloan Kettering Cancer CenterORCID 0000-0003-2700-6309Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Alain R. BonnyiD· 1 shared Alp Gorgulu· 1 shared Anna Pamela CalinawaniD· 1 shared Ash TewariiD· 1 shared Boris A. RevaiD· 1 shared Charlotte J. Bell· 1 shared Clara SchimmeriD· 1 shared Elaine V. FuchsiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Alain R. BonnyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologybioRxivPreprintSep 4, 2026

E-cadherin-mediated neighborhood surveillance dictates pre-malignant outcomes

Elizabeth A.N. Thompson, Clara Schimmer, Tatiana Omelchenko…·Stephanie J. Ellis

The paper shows E-cadherin redistribution creates tension heterogeneity, triggering cell competition that eliminates pre-malignant cells, but this system can fail, leading to tumor susceptibility.

DOI 10.64898/2026.09.02.748765

mouseexperimental assay

𝕏 PostBluesky

BioinformaticsbioRxivPreprintOct 19, 2020

Prioritization of prostate cancer to immune checkpoint therapy by ranking tumors along IFN-γ axis and identification of immune resistance mechanisms

Boris A. Reva, Tatiana Omelchenko, Anna Pamela Calinawan…·Ash Tewari

This study ranks prostate cancer tumors along the IFN-γ/PD-L1 axis to prioritize patients for immune checkpoint therapy and identifies immune resistance mechanisms.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky